Quick Answer
ALX ONCOLOGY HOLDINGS INC reported Cash And Cash Equivalents At Carrying Value of $16.37 million for the year ending 2025.
- ALX ONCOLOGY HOLDINGS INC showed a decrease of -6.8% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from ALX ONCOLOGY HOLDINGS INC's annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $98.10 million | Q3 2020: $259.48 million | Q1 2021: $429.86 million | Q2 2021: $409.96 million | Q3 2021: $385.15 million | Q1 2022: $159.09 million | Q2 2022: $66.38 million | Q3 2022: $49.05 million | Q1 2023: $63.19 million | Q2 2023: $38.04 million | Q3 2023: $19.58 million | Q1 2024: $14.04 million | Q2 2024: $15.53 million | Q3 2024: $16.10 million | Q1 2025: $20.61 million | Q2 2025: $19.30 million | Q3 2025: $23.44 million.
- Over the full 7 years of available data (2019 to 2025), ALX ONCOLOGY HOLDINGS INC's Cash And Cash Equivalents At Carrying Value has grown by 81.6%.
- Historical annual values: Fiscal year 2025: $16.37 million | Fiscal year 2024: $17.57 million | Fiscal year 2023: $22.41 million | Fiscal year 2022: $48.82 million | Fiscal year 2021: $363.67 million | Fiscal year 2020: $434.22 million | Fiscal year 2019: $9.02 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: